Resilience Biotechnologies Inc.

Purpose

The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing: •Existing space within the facility •Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT